Scarica l'app Stockscreener
43.89
0.09%
0.04
Dopo l'orario di chiusura:
43.89
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$43.85
Aprire:
$43.85
Volume 24 ore:
144.74K
Relative Volume:
0.66
Capitalizzazione di mercato:
$775.92M
Reddito:
$48.56M
Utile/perdita netta:
$25.56M
Rapporto P/E:
27.93
EPS:
1.5712
Flusso di cassa netto:
$-14.09M
1 W Prestazione:
+3.27%
1M Prestazione:
+4.28%
6M Prestazione:
+61.30%
1 anno Prestazione:
+67.71%
Intervallo 1D:
$43.58
$44.01
Intervallo di 1 settimana:
$42.24
$44.01
Portata 52W:
$22.29
$44.01
Xoma Royalty Corp Stock (XOMA) Company Profile
Nome
Xoma Royalty Corp
Settore
Industria
Telefono
510-204-7239
Indirizzo
2200 POWELL STREET, EMERYVILLE, CA
Compare XOMA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XOMA
Xoma Royalty Corp
|
43.89 | 775.21M | 48.56M | 25.56M | -14.09M | 1.5712 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xoma Royalty Corp Stock (XOMA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-17 | Iniziato | The Benchmark Company | Buy |
| 2024-04-29 | Iniziato | Leerink Partners | Outperform |
| 2021-09-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-06-29 | Iniziato | Aegis Capital | Buy |
| 2021-01-19 | Reiterato | H.C. Wainwright | Buy |
| 2018-01-18 | Reiterato | H.C. Wainwright | Buy |
| 2017-10-17 | Ripresa | H.C. Wainwright | Buy |
| 2017-09-05 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2017-06-12 | Iniziato | H.C. Wainwright | Buy |
| 2016-11-14 | Downgrade | Wedbush | Outperform → Neutral |
| 2016-03-11 | Reiterato | Wedbush | Outperform |
| 2015-07-23 | Downgrade | Jefferies | Buy → Hold |
| 2015-07-22 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2015-07-22 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2014-10-10 | Ripresa | ROTH Capital | Buy |
| 2014-04-29 | Aggiornamento | MLV & Co | Hold → Buy |
| 2014-03-11 | Downgrade | MLV & Co | Buy → Hold |
| 2014-03-05 | Reiterato | Ladenburg Thalmann | Buy |
| 2013-10-31 | Reiterato | MLV & Co | Buy |
| 2013-05-09 | Reiterato | Ladenburg Thalmann | Buy |
| 2012-05-14 | Iniziato | Cowen & Co | Outperform |
| 2011-03-31 | Reiterato | MLV Capital | Buy |
| 2011-03-23 | Reiterato | RBC Capital Mkts | Outperform |
| 2011-01-06 | Reiterato | Ladenburg Thalmann | Buy |
| 2011-01-04 | Reiterato | Wedbush | Outperform |
Mostra tutto
Xoma Royalty Corp Borsa (XOMA) Ultime notizie
Ligand Pharmaceuticals Is Buying Xoma for Nearly $740 Million -- WSJ - Moomoo
XOMAO Stock Price, Quote & Chart - ChartMill
XOMA Royalty (XOMA) Stock Fair Value Falls After Ligand Agrees Cash Acquisition - Yahoo Finance
XOMA Royalty Sets July Vote on $39-per-Share Ligand Takeover and Reorganization - TipRanks
XOMA Royalty Corp (XOMA) Institutional Confidence - TradingKey
XOMA Corp8.375% DP PFD B declares $0.5234 dividend - MSN
XOMA Royalty Corp (XOMA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
XOMA Royalty Corp (XOMA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
XOMA Royalty Corp (XOMA) Valuation: PE, PB & Fair Value Analysis - TradingKey
XOMA Royalty Corp (XOMA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
XOMA Royalty Corp (XOMA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
XOMAP | XOMA Royalty Corporation 8.625% Insider Trading - Quiver Quantitative
XOMA Royalty Corp (XOMA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
XOMA Royalty Corp (XOMA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
XOMA Royalty Corp (XOMA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
XOMA Q1 2026 Earnings: EPS Misses Expectations, No Revenue ReportedQuarterly Financial Update - newsline.com
XOMA Royalty Corp Declares Preferred Stock Dividend, Announces Redemption and CVR Record Date Ahead of Ligand Merger – Minichart - Minichart
XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date - The Manila Times
XOMA Details Merger Timeline and Preferred Share Redemption - TipRanks
XOMA Royalty (XOMA) Holds Steady Near $42 as Trading Range Remains IntactPCR Extreme - newsline.com
XOMA Royalty expects HoldCo acquisition to close ~July 14; redeems preferred stock - TradingView
XOMA (XOMA) to redeem all preferred shares and issue CVRs ahead of Ligand deal - Stock Titan
Investors in XOMA face preferred stock redemption, new CVR rights - Stock Titan
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-TMHC, CZR, XOMA, and RAMP - The Malaysian Reserve
XOMAO Q1 2026 Earnings: Preferred Stock EPS Misses Consensus as Revenue AbsentEPS Growth Report - dars.gov.et
Ligand to Buy XOMA Royalty (NASDAQ: XOMA) for $39.00 Cash Plus CVR - Stock Titan
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger–TMHC, CZR, XOMA, and RAMP - Weekly Voice
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--TMHC, CZR, XOMA, and RAMP - Sahm
XOMA Royalty Holds Steady Near Support Levels After Modest GainDividend Stock Picks - newsline.com
XOMA Royalty Holds Steady Near $42 as Resistance at $44.28 LoomsMFI Oversold - newsline.com
XOMAO Q1 2026 Earnings: EPS Misses Estimates Amidst Royalty Revenue ChallengesEarnings Sentiment Score - dars.gov.et
Ligand set to report earnings as XOMA deal reshapes growth outlook - Investing.com
XOMA (XOMA) Q4 2025 Earnings Call Transcript - AOL.com
Ligand Shares Hold Up in Biotech Rout While XOMA Deal Heads for Investor Vote - Bez Kabli
XOMA ROYALTY CORPXOMA 8 5/8 PERP (XOMAP) Stock Price & Overview - ChartMill
[Form 4] XOMA Royalty Corp Insider Trading Activity - Stock Titan
Director at XOMA (XOMA) granted 3,586 RSUs vesting over 12 months - Stock Titan
Director at XOMA (NASDAQ: XOMA) granted 3,586 RSUs vesting over 12 months - Stock Titan
XOMA Royalty Corp (XOMA) director receives 3,586 RSU equity grant - Stock Titan
Equity grant: XOMA (XOMA) director awarded 3,586 RSUs of common stock - Stock Titan
XOMAXOMA Royalty Corp Stock Price and Quote - Finviz
XOMA Royalty (XOMA) merger: $39.00 cash + one CVR tied to Janssen litigation - Stock Titan
XOMAP Q1 2026 Earnings: EPS Misses Estimates Amid Ongoing Royalty FluctuationsBasic EPS Analysis - thelegaladvocate.com
Saying Goodbye To The XOMA Royalty PFDs (NASDAQ:XOMAO) - Seeking Alpha
XOMA Royalty Corporation (Formerly XOMA Corp) Files Form 8-K Detailing Bylaws Amendments and Stock Awards – May 2026 - Minichart
XOMA Royalty shareholders approve incentive plan amendments and bylaw changes By Investing.com - Investing.com South Africa
XOMA Royalty shareholders approve incentive plan amendments and bylaw changes - Investing.com UK
XOMA (NASDAQ: XOMA) shareholders approve equity plans and new bylaw provisions - Stock Titan
XOMAO Stock Price and Chart — NASDAQ:XOMAO - TradingView
BVF group (NASDAQ: XOMA) converts 5,003 Series X preferred into common - Stock Titan
BVF group boosts XOMA (XOMA) ownership to 43.3% after Series X share conversion - Stock Titan
Xoma Royalty Corp Azioni (XOMA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Xoma Royalty Corp Azioni (XOMA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Montano Maricel Perea | Chief Legal Officer |
Apr 20 '26 |
Option Exercise |
0.00 |
3,370 |
0 |
41,793 |
| Hughes Owen | Chief Executive Officer |
Apr 20 '26 |
Option Exercise |
0.00 |
10,568 |
0 |
191,264 |
| Sitko Bradley | Chief Investment Officer |
Apr 20 '26 |
Option Exercise |
0.00 |
3,737 |
0 |
82,961 |
| Trigilio Jeffrey | Chief Financial Officer |
Apr 13 '26 |
Option Exercise |
0.00 |
4,000 |
0 |
94,000 |
| LIMBER JOSEPH M | Director |
Mar 27 '26 |
Option Exercise |
11.20 |
3,026 |
33,891 |
9,234 |
| WYSZOMIERSKI JACK L | Director |
Mar 24 '26 |
Option Exercise |
11.20 |
3,026 |
33,891 |
21,530 |
| Hughes Owen | Chief Executive Officer |
Dec 04 '25 |
Buy |
25.05 |
100,000 |
2,505,000 |
102,000 |
| Sitko Bradley | Chief Investment Officer |
Sep 19 '25 |
Option Exercise |
0.00 |
6,712 |
0 |
19,822 |
| Hughes Owen | Chief Executive Officer |
Sep 19 '25 |
Option Exercise |
0.00 |
35,567 |
0 |
98,268 |
| BURNS THOMAS M. | SVP, Finance & CFO |
Sep 19 '25 |
Option Exercise |
0.00 |
11,846 |
0 |
34,409 |
1.17%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):